- Home
- CRBU vs NBTX Comparison
CRBU vs NBTX Comparison
Compare CRBU & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- NBTX
- Stock Information
- Founded
- CRBU 2011
- NBTX 2003
- Country
- CRBU United States
- NBTX France
- Employees
- CRBU N/A
- NBTX N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRBU Health Care
- NBTX Health Care
- Exchange
- CRBU Nasdaq
- NBTX Nasdaq
- Market Cap
- CRBU 188.8M
- NBTX 211.9M
- IPO Year
- CRBU 2021
- NBTX 2020
- Fundamental
- Price
- CRBU $1.90
- NBTX $6.90
- Analyst Decision
- CRBU Strong Buy
- NBTX Strong Buy
- Analyst Count
- CRBU 4
- NBTX 1
- Target Price
- CRBU $8.50
- NBTX $8.00
- AVG Volume (30 Days)
- CRBU 1.8M
- NBTX 7.4K
- Earning Date
- CRBU 08-12-2025
- NBTX 09-17-2025
- Dividend Yield
- CRBU N/A
- NBTX N/A
- EPS Growth
- CRBU N/A
- NBTX N/A
- EPS
- CRBU N/A
- NBTX N/A
- Revenue
- CRBU $9,918,000.00
- NBTX N/A
- Revenue This Year
- CRBU $9.52
- NBTX N/A
- Revenue Next Year
- CRBU N/A
- NBTX $74.67
- P/E Ratio
- CRBU N/A
- NBTX N/A
- Revenue Growth
- CRBU N/A
- NBTX N/A
- 52 Week Low
- CRBU $0.66
- NBTX $2.76
- 52 Week High
- CRBU $3.00
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- CRBU 53.41
- NBTX 69.47
- Support Level
- CRBU $1.86
- NBTX $6.09
- Resistance Level
- CRBU $2.13
- NBTX $7.03
- Average True Range (ATR)
- CRBU 0.22
- NBTX 0.41
- MACD
- CRBU -0.05
- NBTX 0.05
- Stochastic Oscillator
- CRBU 15.76
- NBTX 83.47
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.